Eosinophilic granulomatosis with polyangiitis presenting with myositis: case based review

被引:0
作者
Sahil Koppikar
Ghaydaa Al-dabie
Dana Jerome
Ophir Vinik
机构
[1] University of Toronto,Division of Rheumatology
[2] University of Toronto,Division of Rheumatology, Women’s College Hospital
[3] St. Michael’s Hospital,Division of Rheumatology
来源
Rheumatology International | 2020年 / 40卷
关键词
Eosinophilic granulomatosis with polyangiitis (EGPA); ANCA vasculitis; MPO vasculitis; Myositis; Eosinophilic myositis;
D O I
暂无
中图分类号
学科分类号
摘要
Eosinophilic granulomatosis with polyangitis (EGPA) is a systemic necrotizing small-vessel vasculitis that presents heterogeneously as a multi-organ disease. EGPA evolves through three phases: (1) prodromic phase with asthma, atopy and sinusitis, (2) eosinophilic phase characterized by peripheral eosinophilia and eosinophilic infiltration without necrosis, and (3) vasculitic phase involving organ damage. EGPA often presents with asthma, mononeuritis multiplex, lung infiltrates, sinusitis and constitutional symptoms. Although myalgias are common, EGPA rarely presents with true weakness with elevated creatinine kinase (CK). We describe a rare case of a patient presenting with eosinophilic myositis, who subsequently developed fulminant EGPA. The patient’s diagnosis was supported by an initial clinical presentation of weakness and elevated CK, followed by fleeting pulmonary infiltrates and mononeuritis multiplex, peripheral eosinophilia, and strongly positive myeloperoxidase anti-cytoplasmic antibody (MPO-ANCA). Muscle biopsy revealed eosinophilic myositis. The patient responded well to high-dose glucocorticoids and cyclophosphamide with improved symptoms and biochemical markers. Based on our literature review, there are only seven similar cases reported of EGPA presenting with myositis and confirmatory muscle biopsies. There is significant heterogeneity in their clinical findings, histopathology and treatments that were used. Our case report and literature review highlights the importance of recognizing myositis as an initial presenting symptom of EGPA, providing an opportunity for early diagnosis and treatment to reduce risk of further disease progression and morbidity.
引用
收藏
页码:1163 / 1170
页数:7
相关论文
共 186 条
[1]  
Greco A(2015)Churg–Strauss syndrome Autoimmun Rev 14 341-348
[2]  
Rizzo MI(2009)Churg–Strauss syndrome Kidney Int 76 1006-1011
[3]  
De Virgilio A(1999)Churg–Strauss syndrome. Clinical study and long-term follow-up of 96 patients Medicine (Baltimore) 78 26-37
[4]  
Gallo A(2013)Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): clinical characteristics and long-term follow up of the 383 patients enrolled in the French Vasculitis Study Group cohort Arthritis Rheum 65 270-281
[5]  
Fusconi M(2005)Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome Arthritis Rheum 52 2926-2935
[6]  
Ruoppolo G(2017)Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk Rheumatol Int 37 151-167
[7]  
Altissimi G(2005)Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome Ann Intern Med 143 632-638
[8]  
De Vincentiis M(2014)Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting as diffuse myositis BMC Musculoskelet Disord 15 1471-2474
[9]  
Vaglio A(2020)Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease Expert Rev Clin Immunol 16 51-61
[10]  
Casazza I(2009)Churg–Strauss syndrome presenting as myositis following unaccustomed exercise J Clin Neurosci 16 1232-1233